Install
The Manila Times is a national daily newspaper in the Philippines that delivers trusted, quality content in print and digital editions.
- 6,383articles · 30d
- 3+ hour agolatest article
- Aug 15, 2026earliest in window
- 91%with images
- 271avg words
- Economy, Business & Finance 3,001
- Finance & Business 2,325
- News 1,951
- Business & Industrial 775
- Politics 622
- Finance 561
- Science & Technology 441
- Arts, Culture, Entertainment & Media 431
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Never Fight Alone Turns Five: Crisis Text Line and Gears of War Reinforce Commitment to Suicide Prevention
3+ day, 18+ hour ago (112+ words) Milestone partnership has supported more than 16,000 conversations with people in mental health crisis since 2021 This will be Gears of War’s fifth year donating 1% of all net revenue from its games and merchandise to Crisis Text Line. Over the past five…...
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
4+ day, 21+ hour ago (190+ words) Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company…...
ViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury
5+ day, 48+ min ago (468+ words) Investment supports application of ViaNautis’ polyNaut® platform to regenerative therapies for spinal cord injury, where targeted delivery remains a huge barrierAdds a new high-value CNS indication and provides further validation of polyNaut® as a versatile platform for precise, non-viral delivery…...
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
5+ day, 2+ hour ago (200+ words) The Commercial Opportunity for GENFIT Beyond the United States - In Europe and Asia, GENFIT expects its IVD2 strategy to play a key role in the future commercialization of its NISTM Technology. Supported by the anticipated expansion of the MASH therapeutic market…...
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
5+ day, 14+ hour ago (120+ words) The Manila Times OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today…...
Maverick Medical AI Brings Revenue Certainty to the Hospital Revenue Cycle
5+ day, 12+ hour ago (237+ words) The Manila Times Maverick Medical AI Brings Revenue Certainty to the Hospital Revenue Cycle Clinical-to-Revenue Intelligence identifies and addresses revenue-impacting issues from the point of care through claim submission, before they reach the payer WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Maverick…...
‘Secondhand smoke causes 1.7M deaths’
5+ day, 16+ hour ago (279+ words) Tobacco remains a leading cause of disease globally, the study said, noting many “non-smokers exposed to secondhand smoke” were among the estimated total of 8 million people who died in 2023 of smoking-related illnesses. “Exposure to secondhand smoke is a globally recognized…...
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
5+ day, 21+ hour ago (723+ words) The Manila Times Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and…...
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
6+ day, 3+ hour ago (465+ words) The Manila Times Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) Ad hoc announcement pursuant to Art. 53 LR - HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive…...
Second-hand smoke causes to nearly 1.7M deaths globally — study
6+ day, 5+ hour ago (301+ words) Tobacco remains a leading cause of disease globally, the study said, noting many "non-smokers exposed to second-hand smoke" were among the estimate total of 8 million people who died in 2023 of smoking-related illnesses. "Exposure to second-hand smoke is a globally recognised…...